Aesthetics

Theodore Rosen, MD, highlights the need for communication with patients about the potential harm of using skin-whiteners.

In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Collin M. Blattner, DO, FAAD, about perspective-changing complications, the future of aesthetic conferences, and the importance of allied health care providers.

Veronica Richardson, MSN, ANP-BC, DCNP, discussed how she diagnoses hair loss subtypes in her session at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium.

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Chinese patients with moderate to severe crow’s feet lines reported high levels of satisfaction with onabotulinumtoxinA treatment, according to a recently published study.

A comprehensive review explored new uses of this popular technology in aesthetic and medical dermatology.

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

In this week’s Pointers with Dr Portela, the 208SkinDoc lists the top 5 ingredients to look for when patients are choosing over the counter solutions.

In this video interview, Darren Smith, MD, comments on the Renuvion/J-Plasma device (Apyx Medical) receiving an FDA warning for dermal resurfacing or skin contraction. He dives into how the device may be causing these issues, how this affects patients, and more.

A multicenter investigation provides information on the prevalence and incidence of alopecia areata in children.

“Microneedling has been touted to the consumer as a means to enhance the penetration of moisturizers, vitamins, skin-lightening ingredients, and other cosmeceuticals. Is this enhanced penetration good? It depends.”

In this week’s Pointers with Dr Portela, the 208SkinDoc highlights alopecia, discussing the different types, and the emotional impact of hair loss.

Dermatology Times® invites medical professionals in the dermatology community to speak out on the vital issues facing the specialty.

The company reported positive results from the PEARL-1 clinical phase 1 study regarding KB301 as an investigational gene-based treatment to address the underlying biology of aging skin.

Terri Phillips, MD, FAAP, expands on her letter to the editor in the April issue of Dermatology Times® diving into how her experience has shaped the her view of the aesthetics industry, the challenges both physicians and patients face, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc attended the 2022 American Academy of Dermatology (AAD) Annual Meeting and talked to several dermatologists about skin care and common misconceptions about this topic.

The skincare manufacturer and distributer announced that it has received patents for hair growth and melasma.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of March.

The company’s combined the need for science advancement with a booth that kept people coming back.

What’s new in body skin care? According to Neil Sadick, MD, FACP, FAACS, FACph, FAAD, all fingers point to these methods.

In his presentation at the recent AAD, Neil Sadick, MD, FACP, FAACS, FACph, FAAD, highlighted new cosmeceutical concepts for the body, including the whole-body rejuvenation program and AM/PM approach.

Christopher Bunick, MD, PhD, offered pointers on how to address the physical and mental aspects of this complex disease in this exclusive interview in conjunction with the American Academy of Dermatology 2022 Annual Meeting.

In this week’s Pointers with Dr Portela, the 208SkinDoc answers the question, “Should I be taking a collagen supplement?” He breaks down the evidence as the answer is not as simple as it may seem.

Anne M Chapas, MD, FAAD, discusses what to do when cosmetic procedures go wrong during a presentation at the AAD 2022 annual meeting.

Master the dialogue about food and skin, hair and nail health.

A poster presented at AAD 2022 dives into one of the largest barriers in obtaining gender-affirming neurotoxin and filler treatment for patients—the cost.

In this video interview, we sit down with Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, to discuss her 2022 AAD annual meeting presentation on alopecia areata. We dive into pipeline possibilities, what current treatments are missing, and more.

Laser hair removal was the most litigated.

On March 14, the FDA released a warning for both consumers and health care providers against the use of the Renuvion/J-Plasma device (Apyx Medical) for dermal resurfacing or skin contraction.